Screening for cancer: concepts and controversies

Area of Science:

• Family Medicine
• Preventive Healthcare
• Oncology

Background:

• Early cancer detection is crucial in family medicine, with patient expectations for screening tests sometimes exceeding evidence-based recommendations.
• Understanding screening controversies is essential for family physicians to provide accurate patient advice.
• Awareness of lead-time, length-time, and overdiagnosis biases is critical to avoid overestimating screening benefits.

Purpose of the Study:

• To review fundamental concepts of cancer screening for family physicians.
• To discuss methods for evaluating screening test efficacy and magnitude of benefit.
• To provide guidance on current screening recommendations and controversies.

Main Methods:

• Literature review of fundamental screening concepts and biases.
• Analysis of evidence supporting cancer screening tests.
• Examination of guidelines from organizations like the U.S. Preventive Services Task Force.

Main Results:

• Randomized controlled trials demonstrating reduced disease-specific or all-cause mortality are the gold standard for evaluating screening benefits.
• The number needed to screen (NNS) metric highlights that significant numbers of asymptomatic individuals may need screening to prevent a single death.
• Specific recommendations include screening for colorectal cancer (ages 50-75) and against prostate-specific antigen (PSA) testing for prostate cancer.
• Lung cancer screening with low-dose computed tomography (LDCT) shows mortality reduction in high-risk individuals but carries risks of false positives, radiation exposure, and overdiagnosis.

Conclusions:

• Family physicians need a strong grasp of screening principles to navigate patient expectations and evidence.
• Rigorous evaluation methods, such as randomized controlled trials, are necessary to accurately assess screening test benefits.
• Screening decisions must weigh potential benefits against harms like overdiagnosis and false positives, especially for tests like LDCT lung cancer screening, which should be coupled with smoking cessation.